Last reviewed 2026-04-22 · How we verify

nucleoside analogue sparing HAART regimen

A nucleoside analogue-sparing antiretroviral regimen uses protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors to suppress HIV replication without the toxicity associated with nucleoside reverse transcriptase inhibitors.

A nucleoside analogue-sparing antiretroviral regimen uses protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors to suppress HIV replication without the toxicity associated with nucleoside reverse transcriptase inhibitors. Used for HIV-1 infection (treatment-naive or treatment-experienced patients).

At a glance

Mechanism of action

This regimen strategy avoids nucleoside analogues (NRTIs) such as AZT, which are associated with mitochondrial toxicity, lipodystrophy, and metabolic complications. Instead, it relies on alternative drug classes—typically a ritonavir-boosted protease inhibitor combined with a non-nucleoside reverse transcriptase inhibitor (NNRTI)—to achieve viral suppression while reducing long-term toxicity burden.

Approved indications

• HIV-1 infection (treatment-naive or treatment-experienced patients)

Common side effects

• Lipid elevation (cholesterol, triglycerides)
• Gastrointestinal disturbance
• Hepatotoxicity
• Rash (NNRTI-related)
• Hyperglycemia

Key clinical trials

• Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• nucleoside analogue sparing HAART regimen CI brief — competitive landscape report
• nucleoside analogue sparing HAART regimen updates RSS · CI watch RSS
• Danish HIV Research Group portfolio CI